Figure 4 from Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma

2026 Open access

Read full text
Authors: Robert L. Hollis, Austin Miller, Heather A. Lankes, Kwong‐Kwok Wong, William Rodgers, David W. M. Millan, Karen Carty, Robert Louis Coleman, Kathleen N. Moore, Angeles Alvarez Secord, David M. O’Malley, John K. Chan
+13 more Andrea R. Hagemann, Stephanie L. Gaillard, Saketh R. Guntupalli, Mitchell I. Edelson, Peter Graham Rose, Oliver Dorigo, Susana N. Banerjee, Ailith Ewing, Michael Churchman, Anil K. Sood, C. Simon Herrington, Charlie Gourley, David Marc Gershenson
DOI: 10.1158/1078-0432.31353244
Cited by: 0

Abstract

Molecular landscape of tumor samples from patients enrolled in GOG281/LOGS. MAPK-associated, MAPK-associated genes as defined in the Gene Ontology Term GO:0000165; Chr1pq-aberrant, chr1p-loss with concurrent chr1q-gain.

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment BRCA gene mutations in cancer Ovarian function and disorders

Publication details

Publication date
17 February 2026
Language
EN